Arrowhead Pharmaceuticals Says MHRA Grants Marketing Authorisation For REDEMPLO For FCS In Adults

What happened

Arrowhead Pharmaceuticals said the MHRA granted marketing authorisation for REDEMPLO (plozasiran) for adults with familial chylomicronaemia syndrome (FCS) in England and Wales, and UK NICE recommends NHS funding for genetically confirmed FCS in adults.

Confirmed

Global impact / market context

The UK approval and NHS funding recommendation give Arrowhead a route to revenue from REDEMPLO in England and Wales. This matters for investors because it can support the company's cash available and help offset spending on research and development.

Analyst inference

The decision applies specifically to genetically confirmed FCS in adults, a narrow patient group. Investor attention is likely to focus on how quickly NHS funding turns into actual sales and cash available, rather than on broader market sentiment.

Analyst inference

What to watch

1. MHRA granted marketing authorisation for REDEMPLO (plozasiran) for FCS in adults, and NICE recommends NHS funding for genetically confirmed FCS in adults in England and Wales. Confirmed
2. Watch for details on when NHS funding starts and how patients in England and Wales gain access, which shapes how soon REDEMPLO can generate revenue. Proposed
3. Track whether prescriptions and revenue from REDEMPLO grow enough to cover ongoing research and development costs, affecting profit per sale and cash available. Analyst inference

Evidence

• Original source link unavailable